May 19, 2011—Arterial Remodeling Technologies (ART) announced details of the state-of-the-art design of its polymer-based bioresorbable stent platform at EuroPCR 2011.
The presentation was made May 18 by Antoine LaFont, M.D., Ph.D., professor of medicine, head interventional cardiology department, Georges Pompidou Hospital (Paris); and, past chairman, Interventional Cardiology Group, European Society of Cardiology (ESC). LaFont is a co-founder of ART.
On Thursday, May 19, also at EuroPCR, LaFont made a second presentation from the podium, disclosing additional data that further validates ART’s innovative approach to simultaneously balance biocompatibility, biomechanics and bioresorption in a bioresorbable PLA (polylactic acid) stent. These data will show that ART’s PLA-based stent can be overexpanded by up to 25% without any problems, thus avoiding the serious medical issues caused by cracking or malapposition.
ART’s novel biopolymers have been developed in conjunction with one of the world’s leading authorities in polymer chemistry, Professor Michel Vert, who is Former Director of the Research Center for Artificial Biopolymers at France’s National Center for Scientific Research (Centre National de Recherche Scientifique/CNRS).
For more information: www.art-stent.com
May 06, 2026 
